MedTrace Logo

Clinical Study of Apatinib and XELOX Combination Regimen to Treat Colorectal Cancer Patients

NCT02829385 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2016-07-12

No results posted yet for this study

Summary

This study makes an observation over the objective response rate of Apatinib and XELOX combination regimen in the first-line treatment of metastatic colorectal cancer. All the participants will receive the treatment of Apatinib and XELOX combination regimen.

Conditions

  • Colorectal Neoplasms

Interventions

DRUG

Apatinib and XELOX combined treatment group

Apatinib Mesylate Tablets 500 mg P.O.d1-21 and XELOX (oxaliplatin 130mg/㎡ i.v. d1, capecitabine 1000mg P.O. d1-d14) Every 3-week time is a cycle until PD or intolerance of drug toxicity occurs.

Sponsors & Collaborators

  • Shoucheng Ma

    lead OTHER

Principal Investigators

  • Da Zhao, Bachelor · Cancer Center of the First Hospital of Lanzhou University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2017-12-31
Completion
2018-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02829385 on ClinicalTrials.gov